In last trading session, Syros Pharmaceuticals Inc (NASDAQ:SYRS) saw 10.66 million shares changing hands with its beta currently measuring 1.68. Company’s recent per share price level of $0.08 trading at $0.0 or -9.14% at ring of the bell on the day assigns it a market valuation of $2.05M. That closing price of SYRS’s stock is at a discount of -8562.5% from its 52-week high price of $6.93 and is indicating a premium of 12.5% from its 52-week low price of $0.07. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 83.63 million shares which gives us an average trading volume of 15.70 million if we extend that period to 3-months.
For Syros Pharmaceuticals Inc (SYRS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.00. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information
Upright in the red during last session for losing -9.14%, in the last five days SYRS remained trading in the red while hitting it’s week-highest on Tuesday, 03/11/25 when the stock touched $0.08 price level, adding 73.05% to its value on the day. Syros Pharmaceuticals Inc’s shares saw a change of -66.71% in year-to-date performance and have moved -10.21% in past 5-day. Syros Pharmaceuticals Inc (NASDAQ:SYRS) showed a performance of -56.11% in past 30-days. Number of shares sold short was 0.94 million shares which calculate 0.8 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 5 to the stock, which implies a rise of 98.4% to its current value. Analysts have been projecting 5 as a low price target for the stock while placing it at a high target of 5. It follows that stock’s current price would drop -6150.0% in reaching the projected high whereas dropping to the targeted low would mean a loss of -6150.0% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 21.16% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 74.11% while estimates for its earnings growth in next 5 years are of 52.99%.
Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s Major holders
Insiders are in possession of 0.74% of company’s total shares while institution are holding 33.97 percent of that, with stock having share float percentage of 34.22%. Investors also watch the number of corporate investors in a company very closely, which is 33.97% institutions for Syros Pharmaceuticals Inc that are currently holding shares of the company.
On the other hand, Vanguard Extended Market Index Fund and Fidelity Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 257.63 shares of worth $19709.0 or 0.96% of the total outstanding shares. The later fund manager was in possession of 98.67 shares on Dec 31, 2024 , making its stake of worth around $7548.0 in the company or a holder of 0.37% of company’s stock.
